Ovarian Cancer: Optimizing the Management Based on Mutations and Biomarkers to Direct Treatment with PARP Inhibitors and Immunotherapy – Live

Description

Program Description

---

Click to Go to the Event Registration

As the treatment of ovarian cancer (OC) moves further into personalized medicine, the importance of determining the inherited mutations in cancer susceptibility genes has grown. It is becoming routine to test for germline mutations in the BRCA1 and BRCA2 genes, which are responsible for a significant proportion of OC and are established predictive biomarkers of potential benefit from poly ADP ribose polymerase (PARP) inhibitors. The BRCA mutations and HR-deficiency occur in around 50% of OC, leading to increased response and survival after Poly (ADP-ribose) polymerase inhibitors (PARPis) administration. PARPis represent a breakthrough for OC therapy. On the contrary, immune checkpoint inhibitors (ICIs), another breakthrough therapy for many solid tumors, led to modest results in OC without clinical approvals. Therefore, combinations aiming to overcome resistance mechanisms have become of great interest. Recently, PARPis have been evidenced to modulate tumor microenvironment at the molecular and cellular level, potentially enhancing ICIs responsiveness. This represents the rationale for the combined administration of PARPis and ICIs.

Agenda

---

• Overview of disease characteristics, genetic testing, and risk stratification in ovarian cancer (OC) – Michael Birrer, MD, PhD
• Discuss the use of PARP inhibitors and immunotherapy in the treatment of OC, and the management of adverse events – Brian Slomovitz, MD, MS

Intended Audience

---

Hematologists/oncologists, obstetrician-gynecologists, pathologists, nurse practitioners, physician assistants, and nurses in diagnosing and treating patients with ovarian cancer.

Commercial Supporter

---

Supported by an educational grant from AstraZeneca Pharmaceuticals